In the BioHarmony Drug Report Database

"Preview" Icon

Romosozumab-aqqg

Evenity (romosozumab) is an antibody pharmaceutical. Romosozumab was first approved as Evenity on 2019-04-09. It is used to treat postmenopausal osteoporosis in the USA. It has been approved in Europe to treat osteoporosis. The pharmaceutical is active against sclerostin.

 

Trade Name

 

Evenity
 

Common Name

 

romosozumab
 

ChEMBL ID

 

CHEMBL2107874
 

Indication

 

osteoporosis, postmenopausal osteoporosis
 

Drug Class

 

Monoclonal antibodies: humanized, bone target

Image (chem structure or protein)

Romosozumab-aqqg structure rendering